(lp0
S'CYTRX CORPORATION  Files An 8-K Results of Operations and ... Market Exclusive - 19 hours ago CytRx Corporation on March 15, 2017 issued a press release regarding its financial results for the year ended December 31, 2016.Form 8-K/A CYTRX CORP For: Mar 15 - StreetInsider.comStock in Focus: CytRx Corporation  - TopChronicle'
p1
aS'CytRx Granted Type B Pre-NDA Meeting with US FDA for Registration Pathway with ... PR Newswire  - Jan 4, 2017 LOS ANGELES, Jan. 4, 2017 /PRNewswire/ -- CytRx Corporation , a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, today announced that,&nbsp;...'
p2
aS"CytRx to Present at the 29th Annual ROTH Conference PR Newswire  - Mar 7, 2017 LOS ANGELES, March 7, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...CytRx Corporation  traded with Volume of 1.28 Million shares in ... - The Newburgh PressCytRx Corporation's  stock price is Worth at $0.42 - Hot Stocks Point"
p3
aS'CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common ... PR Newswire  - Dec 13, 2016 LOS ANGELES, Dec. 13, 2016 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into securities purchase agreements with existing&nbsp;...'
p4
aS'CytRx Corporation Announces Pricing of $20 Million Public Offering of Common ... PR Newswire  - Jul 15, 2016 LOS ANGELES, July 15, 2016 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a registered public offering of an aggregate of&nbsp;...'
p5
aS'CytRx Corporation  Plunges 5.35% on February 23 Equities.com - Feb 23, 2017 CytRx Corporation  had a rough trading day for Thursday February 23 as shares tumbled 5.35%, or a loss of $-0.0241 per share, to close at $0.43.CytRx Corporation Risk Points versus Health Care - CML NewsStock Move to Focus: CytRx Corporation  - Is stories'
p6
aS'CytRx: The BASIC Chemistry Seeking Alpha - Oct 26, 2016 This article is meant to explain the general science of CytRx  and why they will continue to fail. We go over basic chemistry of &quot;pH sensitive linkers&quot; - the fundamental platform of CytRx. Further, we want to make it clear that although ...'
p7
aS'CytRx Corporation  Is A Top Contrarian Play Insider Financial - Oct 14, 2016 CytRx Corporation  has been the subject of some serious hit pieces over the last couple of months, on the back of the company announcing what was construed as disappointing results from an ongoing trial of its lead candidate,&nbsp;...'
p8
aS'CytRx to Present at the 19th Annual BIO CEO &amp; Investor Conference PR Newswire  - Feb 6, 2017 LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...'
p9
aS'Is the Options Market Predicting a Spike in CytRx Corp  Stock? Nasdaq - Dec 30, 2016 Clearly, options traders are pricing in a big move for CytRx Corp shares, but what is the fundamental picture for the company?'
p10
a.